Active	Status	Sponsor type	Region	Phase	Filter
4 Active 7 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
zatolmilast (BPN14770) / Shionogi
NCT05358886: A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome	Recruiting	3	150	US	BPN14770/ zatolmilast, Placebo	Tetra Discovery Partners	Fragile X Syndrome	06/25	09/25
NCT05367960: An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome	Enrolling by invitation	3	300	US	Zatolmilast/ BPN14770	Tetra Discovery Partners	Fragile X Syndrome	09/27	12/27
NCT05163808: A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome	Recruiting	2/3	150	US	zatolmilast, BPN14770, Placebo	Tetra Discovery Partners	Fragile X Syndrome	09/25	12/25
NCT06717438: Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])	Not yet recruiting	2	30	US	BPN14770, Zatolmilast, Placebo	Shionogi	Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder	03/26	09/26